



an Open Access Journal by MDPI

Advanced Research in Prostate Cancer 2.0

Guest Editor:

Dr. Ruth Vinall

Department of Pharmaceutical
and Biomedical Sciences,
College of Pharmacy, California
Northstate University, Elk Grove,
CA, USA

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editor

Dear Colleagues,

Over the past few years, we have witnessed major advances in prostate cancer treatments. The trend, as for many cancer types, is moving toward the development and clinical use of biomedicine-based approaches. Large-scale genomics projects have led to the ongoing development of several targeted therapies, and, importantly, the co-development of biomarkers will allow for the prediction and measurement of patient response. This Special Edition of Biomedicines entitled 'Advanced Research in Prostate Cancer' will include reviews that describe major advances which have occurred in the treatment of prostate cancer over the past few years as well as original research articles that describe preclinical and/or translational studies which will support future advances.

On behalf of the Biomedicines journal, it is my pleasure to invite you to submit an article to this Special Edition. Articles should be focused on the development and use, or potential use, of biomedicines. Articles which outline how genetic analyses can guide the development and use of these treatment options, or which describe innovative drug delivery strategies, are also welcomed.



mdpi.com/si/125649

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI